$322.83
1.44% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Stock price

$322.83
+32.73 11.28% 1M
+84.86 35.66% 6M
+87.52 37.19% YTD
+75.83 30.70% 1Y
+176.34 120.38% 3Y
+174.92 118.26% 5Y
+208.62 182.66% 10Y
+315.54 4,328.40% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+4.58 1.44%
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Key metrics

Basic
Market capitalization
$42.1b
Enterprise Value
$40.5b
Net debt
$-1.6b
Cash
$2.6b
Shares outstanding
130.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
17.93 | 14.32
EV/Sales
17.24 | 13.77
EV/FCF
negative
P/B
364.45
Financial Health
Equity Ratio
1.58%
Return on Equity
-414.62%
ROCE
-3.68%
ROIC
-6.97%
Debt/Equity
8.88
Financials (TTM | estimate)
Revenue
$2.3b | $2.9b
EBITDA
$-57.8m | $163.9m
EBIT
$-115.4m
Net Income
$-269.7m | $-179.3m
Free Cash Flow
$-75.4m
Growth (TTM | estimate)
Revenue
17.21% | 30.77%
EBITDA
52.71% | 236.34%
EBIT
34.35%
Net Income
18.77% | 35.54%
Free Cash Flow
-158.96%
Margin (TTM | estimate)
Gross
86.01%
EBITDA
-2.46% | 5.57%
EBIT
-4.91%
Net
-11.49% | -6.10%
Free Cash Flow
-3.21%
More
EPS
$-2.09
FCF per Share
$-0.58
Short interest
3.42%
Employees
2.23k
Rev per Employee
$1.01m
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

30x Buy
77%
8x Hold
21%
1x Sell
3%

Analyst Opinions

39 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
77%
Hold
21%
Sell
3%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,348 2,348
17% 17%
100%
- Direct Costs 328 328
2% 2%
14%
2,020 2,020
20% 20%
86%
- Selling and Administrative Expenses 1,005 1,005
22% 22%
43%
- Research and Development Expense 1,130 1,130
9% 9%
48%
-58 -58
53% 53%
-2%
- Depreciation and Amortization 58 58
8% 8%
2%
EBIT (Operating Income) EBIT -115 -115
34% 34%
-5%
Net Profit -270 -270
19% 19%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Market Watch
10 days ago
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.
Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR...
Neutral
Business Wire
19 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,230
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today